NCT04209426

Brief Summary

This is a single-center retrospective observational cohort study of consecutively operated patients who underwent total hip arthroplasty (THA) with a SYMBOL CUP DMR HA or a SYMBOL CUP DM CEM hemispherical dual mobility acetabular implant. The purpose of this study is to estimate the safety and efficacy of those two implants at two-year follow-up.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Mar 2015

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 18, 2015

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2018

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 14, 2018

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

December 20, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

December 24, 2019

Completed
5.3 years until next milestone

Results Posted

Study results publicly available

April 18, 2025

Completed
Last Updated

April 18, 2025

Status Verified

February 1, 2025

Enrollment Period

3 years

First QC Date

December 20, 2019

Results QC Date

April 5, 2023

Last Update Submit

April 1, 2025

Conditions

Keywords

total hip arthroplastycomplexrevisionhemispherical dual-mobility acetabular cupsafetyefficacyimplant survivalprosthetic dislocation

Outcome Measures

Primary Outcomes (1)

  • Implant Survival: Acetabular Cup Survival at 2-year Follow-up

    This is a the ratio of the number of patient joints surviving with the acetabular prosthesis in position at a given follow-up time (numerator) over the initial number of those joints from the date they received the acetabular prosthesis (denominator). The cumulative ratio is recalculated at each event using the Kaplan-Meier method from the date of each joint index operation through the date of each participant's death or prosthetic removal surgery or loss-to-follow-up or last assessment alive with the acetabular prosthesis in place. The longest duration between the index operation and the final assessment is 2 years.

    2 years as of index operation

Secondary Outcomes (3)

  • Number of Patients With One or Several Post-operative Adverse Events and Count of Each Serious Adverse Event and Aggregate Count of Adverse Events

    2 years as of index operation

  • Harris Hip Score (HHS) at Baseline and 1-year Follow-up

    1 year as of index operation

  • The Modified Harris Hip Score (Modified HHS) at Baseline, 1-year and 2-year Follow-up

    2 years as of index operation

Study Arms (2)

HMB-DMR-HA

Total hip arthroplasty with hemispherical metal-back dual-mobility acetabular cup with tripod fixation consisting of a hydroxyapatite-coated outer surface as well as two pegs and one screw.

Device: THA with SYMBOL CUP DMR HA

HMB-DM-CEM

Total hip arthroplasty with hemispherical metal-back dual-mobility acetabular cup with tripod fixation consisting of a bare metal outer surface to be covered with bone-compatible cement.

Device: THA with SYMBOL CUP DM CEM

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Exhaustive recruitment of patients meeting inclusion and exclusion criteria

You may qualify if:

  • All patients with total hip implant using hemispheric dual-mobility SYMBOL CUP DMR HA or SYMBOL CUP DM CEM
  • Operation performed by the primary investigator
  • Delay between index operation and March 1 2018 has reached 2 years

You may not qualify if:

  • patient refusal to participate in the study
  • minors (age \< 18 years)
  • patients under guardianship

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hôpital Privé Medipole de Savoie

Challes-les-Eaux, 73190, France

Location

Results Point of Contact

Title
Frederic C Daoud, M.D., M.Sc., Epidemiologist-Biostatistician
Organization
Medextens SARL

Study Officials

  • Gilles Estour, M.D.

    Hôpital Privé Medipole de Savoie

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 20, 2019

First Posted

December 24, 2019

Study Start

March 18, 2015

Primary Completion

March 31, 2018

Study Completion

August 14, 2018

Last Updated

April 18, 2025

Results First Posted

April 18, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share

Locations